Equities Analysts Offer Predictions for ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a research report issued on Monday, November 4th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings per share of ($2.24) for the year, up from their prior forecast of ($2.31). HC Wainwright currently has a “Buy” rating and a $400.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.71) EPS, FY2026 earnings at $9.23 EPS, FY2027 earnings at $19.05 EPS and FY2028 earnings at $22.41 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 earnings per share.

A number of other research analysts have also weighed in on the company. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Bank of America increased their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. JPMorgan Chase & Co. lifted their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Needham & Company LLC reiterated a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Six research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $294.50.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $272.22 on Thursday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company’s 50 day simple moving average is $273.88 and its 200 day simple moving average is $229.34.

Institutional Trading of Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Huntington National Bank grew its stake in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Finally, Altitude Crest Partners Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $30,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.